Meeting
2022 ASCO Gastrointestinal Cancers Symposium
Phase II study of durvalumab following neoadjuvant chemoRT in operable rectal cancer: NSABP FR-2.
Authors
Thomas J. George
NSABP Foundation, and The University of Florida Health Cancer Center, Gainesville, FL
Thomas J. George , Greg Yothers , Samuel A. Jacobs , Gene Grant Finley , James Lloyd Wade III, Caio Max Sao Pedro Rocha Lima , Jeffrey Scott Rose , Shalu Pahuja , Anuradha Krishnamurthy , John C. Krauss , Melvin Deutsch , Jesus C. Fabregas , James J. Lee , Carmen Joseph Allegra , Norman Wolmark
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session C: Cancers of the Colon, Rectum, and Anus
Track
Colorectal Cancer,Anal Cancer
Sub Track
Therapeutics
Clinical Trial Registration Number
03102047
DOI
10.1200/JCO.2022.40.4_suppl.099
Abstract #
99
Poster Bd #
E8
Abstract Disclosures
Similar Posters
Poster
2020 Gastrointestinal Cancers Symposium
NSABP FR-2: Phase II study of durvalumab following neoadjuvant chemoRT in stage II-IV rectal cancer.
First Author: Thomas J. George
Poster
2019 Gastrointestinal Cancers Symposium
NSABP FR-2: Phase II study of durvalumab following neoadjuvant chemoRT in stage II-IV rectal cancer.
First Author: Thomas J. George
Poster
2018 ASCO Annual Meeting
NSABP FR-2: Phase II study of durvalumab following neoadjuvant chemotherapy (NAC) in stage II-IV rectal cancer.
First Author: Thomas J. George Jr.
Poster
2024 ASCO Genitourinary Cancers Symposium
Neoadjuvant nivolumab (N) + ipilimumab (I) in cisplatin-ineligible patients with upper tract urothelial cancer (UTUC): Updated results.
First Author: Michal Sternschuss